^
Association details:
| Biomarker: | BRAF G469S |
|---|---|
| Cancer: | Melanoma |
| Drug: | Mektovi (binimetinib) (MEK inhibitor) + Braftovi (encorafenib) (BRAF inhibitor, cRAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
531P - Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Preliminary results of the investigator initiated phase II BEAVER trial
Published date:
09/13/2021
Excerpt:
ORR was 22% (2/9) with a confirmed PR in a pt with ampullary cancer (BRAF D594G, class 3) who continues on treatment for 5.4+ months, and an unconfirmed PR in a melanoma pt (BRAF G469S, class 2) treated for 6.5 months. One gallbladder cancer pt (BRAF D594N, class 3) had SD, treated for 4.4 months....Preliminary data confirmed the safety of B+E and demonstrated evidence of anti-tumor activity in advanced cancer pts with non-V600E BRAF mts.
Source:
Title:
Preliminary results of BEAVER: An investigator-initiated phase II study of binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts)
Published date:
05/19/2021
Excerpt:
Pts receive binimetinib (45mg PO BID) and encorafenib (450mg PO daily)...ORR was 12.5% (1/8) with one unconfirmed PR in a melanoma pt (BRAF G469S), treated for 6.5 months. One gallbladder cancer pt (BRAF D594N) had SD, and 6 pts had PD as best response.
DOI:
10.1200/JCO.2021.39.15_suppl.e15038
